- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01018212
Cicatrix Cream in Cutaneous Groves
December 7, 2010 updated by: Catalysis SL
Effect the Cicatrix Cream in Cutaneous Groves Treatment
The purpose of the study is to assess the effect of CICATRIX (Asian Gotu Kola or Pennywort) usage in the treatment of cutaneous grooves.
The duration of this phase 2 clinical trial will be 4 months.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Havana
-
Havana City, Havana, Cuba, 10400
- Pediatric Hospital Juan Manuel Marquez
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent
Exclusion Criteria:
- Patient that refer manifestations of high sensibility to the medication or to some of the components of the product.
- Patient that don't want to participate in the study.
- Patient not very cooperative.
- Responsible family not very cooperative.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: A
Cicatrix cream
|
We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations. The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
They are the cutaneous grooves, being Observed the reduction of the number of the lesions monthly.
Time Frame: 4 month
|
4 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Extension of the groves and the reduction of these expressed in centimetres
Time Frame: 4 months
|
4 months
|
|
Adverse effects
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Fernanda Pastrana, MD, Pediatric Hospital Juan Manuel Marquez
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
November 20, 2009
First Submitted That Met QC Criteria
November 20, 2009
First Posted (Estimate)
November 23, 2009
Study Record Updates
Last Update Posted (Estimate)
December 8, 2010
Last Update Submitted That Met QC Criteria
December 7, 2010
Last Verified
December 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAT-0902-CU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Groves
-
First Affiliated Hospital of Chongqing Medical...Not yet recruitingPrimary Cutaneous Amyloidosis
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Active, not recruitingClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterBristol-Myers Squibb; Array BioPharmaTerminatedMetastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Locally Advanced Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC V8 | Clinical Stage IV Cutaneous Melanoma AJCC V8 | Pathologic Stage III Cutaneous Melanoma AJCC V8 | Pathologic Stage IIIA Cutaneous Melanoma AJCC V8 and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingClinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical Stage IB Cutaneous Melanoma AJCC v8 | Clinical Stage II Cutaneous Melanoma AJCC v8 | Clinical Stage IIA Cutaneous Melanoma AJCC v8 | Clinical Stage IIB Cutaneous Melanoma AJCC v8 | Clinical Stage... and other conditionsUnited States
-
University of California, DavisNational Cancer Institute (NCI)SuspendedClinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage II Cutaneous Melanoma AJCC v8United States
-
Immunovant Sciences GmbHActive, not recruitingSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusSerbia, United States, Argentina, Bulgaria, Canada, Chile, Georgia, Germany, Greece, Poland, Puerto Rico, Spain, United Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
University of California, DavisTerminatedCutaneous SurgeryUnited States
-
David WeinsteinTerminated
-
Children's Oncology GroupNot yet recruitingCutaneous Melanoma | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage II Cutaneous Melanoma AJCC v8 | Cutaneous Melanocytic Neoplasm | Cutaneous Spitz Melanocytoma
Clinical Trials on Cicatrix cream
-
Catalysis SLCompleted
-
Catalysis SLCompleted
-
Catalysis SLCompleted
-
University of North Carolina, CharlotteTeva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States
-
Incyte CorporationCompletedCutaneous Lichen PlanusUnited States, Canada
-
Psoriasis Research Institute of GuangzhouRecruitingPsoriasis Vulgaris | Phase III | Topical AdministrationUnited States
-
Incyte CorporationCompletedHidradenitis SuppurativaUnited States, Canada
-
Incyte CorporationCompletedLichen SclerosusUnited States, Canada
-
Incyte CorporationRecruitingNonSegmental VitiligoUnited Kingdom, Poland, Germany, Spain, Hungary, France, Italy, Argentina, Bulgaria, Belgium, Netherlands, Austria, Denmark, Portugal
-
Incyte CorporationCompletedPrurigoUnited States, Spain, France, Germany, Poland, Italy, Canada, Netherlands, Belgium, Argentina, Chile